Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 189987 | ISIN: CA17965L1004 | Ticker-Symbol: N77
Frankfurt
21.01.25
08:41 Uhr
46,400 Euro
-0,200
-0,43 %
1-Jahres-Chart
CLAIRVEST GROUP INC Chart 1 Jahr
5-Tage-Chart
CLAIRVEST GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
46,40047,20021.01.
GlobeNewswire (Europe)
123 Leser
Artikel bewerten:
(0)

Clairvest Group Inc.: Clairvest Reports Fiscal 2025 First Quarter Results

Finanznachrichten News

TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fiscal 2025 first quarter ended June 30, 2024 and events which occurred subsequent to quarter end. (All figures are in Canadian dollars unless otherwise stated)

Highlights

  • June 30, 2024 book value was $1,186.2 million or $81.02 per share compared with $1,176.3 million or $80.16 per share as at March 31, 2024
  • Net income for the quarter ended June 30, 2024 was $23.9 million or $1.63 per share
  • Clairvest and Clairvest Equity Partners VI ("CEP VI") made two platform investments during the quarter to complete the CEP VI Fund investment program and Clairvest commenced the CEP VII investment program
  • Clairvest and Clairvest Equity Partners V ("CEP V") completed the sale of Durante Rentals
  • Subsequent to quarter end, Clairvest, CEP V and CEP VI completed the sale of FSB Technology
  • Subsequent to quarter end, Clairvest and CEP V completed the sale of Winters Bros. Waste Systems of Long Island
  • Subsequent to quarter end, Clairvest paid $0.8016 in dividends

Clairvest's book value was $1,186.2 million or $81.02 per share as at June 30, 2024, compared with $1,176.3 million or $80.16 per share as at March 31, 2024. For the quarter ended June 30, 2024, Clairvest recorded net income of $23.9 million, or $1.63 per share, which was primarily driven by a net increase in the valuation of Clairvest's private equity investment portfolio. Also during the quarter, Clairvest purchased and cancelled 32,050 common shares at an average price of $70.92/share, or a total cost of $2.3 million, which added $0.03 per share to the book value.

As described in the Clairvest fiscal 2024 fourth quarter and year end press release, Clairvest and CEP VI completed two platform investments during the quarter, completing the CEP VI Fund investment program with a total of fourteen investments. With the completion of the CEP VI investment program, Clairvest commenced the CEP VII investment program which has total committed capital of US$1.2 billion, US$902 million of which is third party capital.

During the quarter, Clairvest and CEP V sold their interest in Durante Rentals at a loss, with proceeds equating to 0.7x what was invested, which was at a small premium to the carrying value at March 31, 2024. Clairvest received US$8 million of sale proceeds.

In July 2024, Clairvest exited FSB Technology and did not receive any proceeds. FSB Technology was previously written off entirely in 2023.

Also in July 2024, Clairvest, CEP V and the Winters family sold Winters Bros. Waste Systems of Long Island ("Winters Bros. Long Island") to Waste Management. Proceeds on the sale generated a 6.8x return on invested capital, or US$57 million for Clairvest. As at June 30, 2024, Clairvest's investment in Winters Bros. Long Island was carried at the exit value. In addition, we anticipate additional proceeds could be generated on the sale of other assets not acquired by Waste Management which could raise the multiple of money realized to over 7x.

"The successful Winters Bros. result is a testament to the business that the Winters Family has built over the past nine years where they grew it into an industry leader on Long Island. We are proud to have been their partner in 3 different waste management investments and hope we can partner with them again," said Ken Rotman, CEO of Clairvest. "At the same time, we pride ourselves on honestly assessing each situation and taking appropriate action, even when unpleasant. Cleaning up the portfolio enables us to focus on our core mission of building assets of strategic significance, which is critical to our ongoing success. While we still have more issues to address, putting the Durante and FSB Technology investments behind us is a step in the right direction. These realized losses, the first in some time, represent catalysts to reassess our process and internalize some lessons learned. Our track record includes 45 exits which generated an aggregate return of 3.8x invested capital; it includes many terrific wins but also 9 losses, of which these are two."

Also subsequent to quarter end, Clairvest paid an annual ordinary dividend of $0.10 per share and a special dividend of $0.7016 per share, such that in aggregate, the dividends represent 1% of the March 31, 2024 book value. Both dividends were paid on July 26, 2024 to common shareholders of record as at July 5, 2024 and are eligible dividends for Canadian income tax purposes.

Summary of Financial Results - Unaudited
Financial Results(1)
Quarter ended
June 30
20242023
($000's, except per share amounts)$$
Net investment gain20,11224,469
Net carried interest from Clairvest Equity Partners III and IV2,124591
Distributions, interest income, dividends and fees16,70311,809
Total expenses, excluding income taxes11,95815,831
Net income and comprehensive income23,92119,462
Basic and fully diluted net income per share1.631.30
Financial Position
June 30March 31,
20242024
($000's, except share information and per share amounts)$$
Total assets1,361,0101,342,139
Total cash, cash equivalents, temporary investments and restricted cash282,572330,193
Carried interest from Clairvest Equity Partners III and IV54,31252,188
Corporate investments(1)929,377870,660
Total liabilities174,802165,842
Management participation from Clairvest Equity Partners III and IV43,10541,506
Book value(2)1,186,2081,176,297
Common shares outstanding14,641,65114,673,701
Book value per share(2)81.0280.16

(1) Includes carried interest of $151,846 (March 31: $143,617) and management participation of $109,761 (March 31: $103,740) from Clairvest Equity Partners V and VI, and $105,360 (March 31: $90,973) in cash, cash equivalents and temporary investments held by Clairvest's acquisition entities.
(2) Book value is a Non-IFRS measure calculated as the value of total assets less the value of total liabilities.

Clairvest's first quarter fiscal 2025 financial statements and MD&A are available on the SEDAR website at www.sedar.com and the Clairvest website at www.clairvest.com.

About Clairvest
Clairvest's mission is to partner with entrepreneurs to help them build strategically significant businesses. Founded in 1987 by a group of successful Canadian entrepreneurs, Clairvest is a top performing private equity management firm with over CAD $4.6 billion of capital under management. Clairvest invests its own capital and that of third parties through the Clairvest Equity Partners limited partnerships in owner-led businesses. Under the current management team, Clairvest has initiated investments in 66 different platform companies and generated top quartile performance over an extended period.

Contact Information
Stephanie Lo
Director, Investor Relations and Marketing
Clairvest Group Inc.
Tel: (416) 925-9270
Fax: (416) 925-5753
stephaniel@clairvest.com

Forward-looking Statements
This news release contains forward-looking statements with respect to Clairvest Group Inc., its subsidiaries, its CEP limited partnerships and their investments. These statements are based on current expectations and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Clairvest, its subsidiaries, its CEP limited partnerships and their investments to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general and economic business conditions and regulatory risks. Clairvest is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or otherwise.

www.clairvest.com


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.